BSG and infection: Our lab recently revealed that CD147 is a receptor mediating cellular entry of SARS-CoV-2.18 In our study, we conducted virus inhibition experiments in vitro with CD147 antibody (Meplazumab), which showed that Meplazumab of low concentration effectively blocked the infection and replication of variants—alpha, beta, gamma, and delta at inhibition rates of 75.7, 52.1, 52.1, and 62.3%, respectively.